Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma

The Egyptian Journal of Otolaryngology

Table 3 Red cell indices of LASCCHN patients in both the groups

	Weekly dose cisplatin (mean dose: 30 mg/m²) (n = 15)			Every 3-week dose cisplatin (mean dose: 100 mg/m²) (n = 15)			Control	ANOVA (p value)
Red cell indices	Pre chemotherapy	Post chemotherapy	Change (%)	Pre chemotherapy	Post chemotherapy	Change (%)	Control	ANOVA (p value)
Hb%	11.5 ± 1.2^a2	9.9 ± 0.8^a2	− 13.9	11.2 ± 1.5	9.9 ± 0.6		12.1 ± 1.7	***
Hematocrit	37.1 ± 4.9	33.9 ± 3.7	− 8.5	37.8 ± 5.7	34.4 ± 3.7	− 9.1	36.9 ± 5.5	ns
MCV	86.9 ± 9.3	78.9 ± 12.6	− 9.3	81.7 ± 20.3	76.6 ± 9.7	− 6.2	90.6 ± 3.1	* (.0161)
MCH	25.4 ± 3.7	26.7 ± 3.9	5.05	26.1 ± 3.9	26.9 ± 3.4	3.1	27.8 ± 1.3	ns

***p < .001 (extremely significant), ns: p < .05 (not significant), *p < .05 (significant)
On comparing the different groups by Tukey-Kramer Multiple comparisons test, the corresponding letters indicate the significance level between groups as follows:
^a2P < .01 (very significant). Changes in terms of decrease in levels are indicated in minus sign